A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
← catalyst calendarSponsored by Eisai Co., Ltd. (industry) · 4523.T — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
51actual
Sites
11
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-10-09 | actual | When the study began enrolling |
| Primary completion | 2026-06-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-18 | actual | The whole study's end, after follow-up |
| First posted | 2020-10-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Neoplasms
Interventions
- Drug: E7090
- Drug: Fulvestrant
- Drug: Exemestane
Primary outcomes
what the primary-completion date above is the date OFPart 1: Recommended Dose (RD) of E7090 in Combination With Other Anticancer Agents
measured Up to Cycle 1 (each cycle length = 28 days)
Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)
measured Up to Cycle 1 (each cycle length = 28 days)
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured Up to 30 days after last administration of study drug (approximately up to 66 months)
Permalink · 4523.T's whole pipeline · Catalyst calendar · Every registered study · What changed